α1-antitrypsin deficiency in lung and liver disease

A. S. Buist

doi:10.1080/21548331.1989.11703712

α₁-antitrypsin deficiency in lung and liver disease

A. S. Buist

Pulmonary and Critical Care Medicine

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Abstract

Prevention of lung disease is the major therapeutic imperative for patients with this genetic disorder. Definitive treatment involves replacement or augmentation of antielastase with human plasma-derived protease inhibitor in patients with early or mild chronic obstructive pulmonary disease. Measures to minimize the risk of serious hepatic involvement remain to be devised.

Original language	English (US)
Pages (from-to)	51-59
Number of pages	9
Journal	Hospital Practice
Volume	24
Issue number	5
DOIs	https://doi.org/10.1080/21548331.1989.11703712
State	Published - 1989

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1080/21548331.1989.11703712

Cite this

@article{99ec16d79ba14faf98d05fde10008d44,

title = "α1-antitrypsin deficiency in lung and liver disease",

abstract = "Prevention of lung disease is the major therapeutic imperative for patients with this genetic disorder. Definitive treatment involves replacement or augmentation of antielastase with human plasma-derived protease inhibitor in patients with early or mild chronic obstructive pulmonary disease. Measures to minimize the risk of serious hepatic involvement remain to be devised.",

author = "Buist, {A. S.}",

year = "1989",

doi = "10.1080/21548331.1989.11703712",

language = "English (US)",

volume = "24",

pages = "51--59",

journal = "Hospital practice (1995)",

issn = "2154-8331",

publisher = "Taylor and Francis Ltd.",

number = "5",

}

TY - JOUR

T1 - α1-antitrypsin deficiency in lung and liver disease

AU - Buist, A. S.

PY - 1989

Y1 - 1989

N2 - Prevention of lung disease is the major therapeutic imperative for patients with this genetic disorder. Definitive treatment involves replacement or augmentation of antielastase with human plasma-derived protease inhibitor in patients with early or mild chronic obstructive pulmonary disease. Measures to minimize the risk of serious hepatic involvement remain to be devised.

AB - Prevention of lung disease is the major therapeutic imperative for patients with this genetic disorder. Definitive treatment involves replacement or augmentation of antielastase with human plasma-derived protease inhibitor in patients with early or mild chronic obstructive pulmonary disease. Measures to minimize the risk of serious hepatic involvement remain to be devised.

UR - http://www.scopus.com/inward/record.url?scp=0024336214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024336214&partnerID=8YFLogxK

U2 - 10.1080/21548331.1989.11703712

DO - 10.1080/21548331.1989.11703712

M3 - Review article

C2 - 2497126

AN - SCOPUS:0024336214

SN - 2154-8331

VL - 24

SP - 51

EP - 59

JO - Hospital practice (1995)

JF - Hospital practice (1995)

IS - 5

ER -

α₁-antitrypsin deficiency in lung and liver disease

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this